title: Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.
abstract: Poliomyelitis caused by wild poliovirus has been virtually nonexistent in the United States since 1980, and vaccine-associated paralytic poliomyelitis (VAPP) has emerged as the predominant form of the disease. We reviewed national surveillance data on poliomyelitis for 1960-1989 to assess the changing risks of wild-virus, vaccine-associated, and imported paralytic disease; we also sought to characterize the epidemiology of poliomyelitis for the period 1980-1989. The risk of VAPP has remained exceedingly low but stable since the mid-1960s, with approximately 1 case occurring per 2.5 million doses of oral poliovirus vaccine (OPV) distributed during 1980-1989. Since 1980 no indigenous cases of wild-virus disease, 80 cases of VAPP, and five cases of imported disease have been reported in the United States. Three distinct groups are at risk of vaccine-associated disease: recipients of OPV (usually infants receiving their first dose), persons in contact with OPV recipients (mostly unvaccinated or inadequately vaccinated adults), and immunologically abnormal individuals. Overall, 93% of cases in OPV recipients and 76% of vaccine-associated cases have been related to administration of the first or second dose of OPV. Our findings suggest that adoption of a sequential vaccination schedule (inactivated poliovirus vaccine followed by OPV) would be effective in decreasing the risk of VAPP while retaining the proven public health benefits of OPV.
authors.affiliation: Division of Immunization, National Center for Prevention Services, Centers for Disease Control, Atlanta, Georgia 30333.
authors.forename: P M
authors.initials: PM
authors.lastname: Strebel
authors.forename: R W
authors.initials: RW
authors.lastname: Sutter
authors.forename: S L
authors.initials: SL
authors.lastname: Cochi
authors.forename: R J
authors.initials: RJ
authors.lastname: Biellik
authors.forename: E W
authors.initials: EW
authors.lastname: Brink
authors.forename: O M
authors.initials: OM
authors.lastname: Kew
authors.forename: M A
authors.initials: MA
authors.lastname: Pallansch
authors.forename: W A
authors.initials: WA
authors.lastname: Orenstein
authors.forename: A R
authors.initials: AR
authors.lastname: Hinman
mesh_terms: D006801:Humans; D011051:Poliomyelitis / Q000453:epidemiology*; D011055:Poliovirus Vaccine, Oral / Q000009:adverse effects*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D011055:Poliovirus Vaccine, Oral